PVLA News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

PV

Mkt Cap

$1.73B

Volume

139.97K

Next Earnings

November 10th

Chart Financials Earnings News About Insider Filings

What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock RallyPalvella Therapeutics' Chief Operating Officer Kathleen Goin sold 4,302 shares worth $476,000 through a pre-planned trading arrangement, while retaining 17,219 options. The sale comes amid a 620% one-year stock surge driven by investor optimism about the company's QTORIN rapamycin therapy for rare skin diseases. The FDA recently granted rolling review for the drug's New Drug Application, with the company targeting NDA completion in H2 2026.The Motley Fool · Jun 27, 2026

Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) SignalPalvella Therapeutics' COO Kathleen Goin sold 4,302 shares worth ~$508,000 on March 18, 2026, through a pre-planned Rule 10b5-1 trading plan adopted in August. The sale should not raise concerns as it was a structured liquidity event tied to option exercises. The stock has surged 340% over the past year, supported by positive Phase 3 results for its lead candidate QTORIN rapamycin (95% of participants showed improvement), a planned New Drug Application submission in H2 2026, and a recent $230 million equity offering.The Motley Fool · Mar 25, 2026

Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional SharesPalvella Therapeutics (NASDAQ: PVLA) closed its upsized public offering on February 27, 2026, raising $230.0 million in gross proceeds by selling 1,840,000 shares at $125.00 per share, including the full exercise of underwriters' option for 240,000 additional shares. The company plans to use the net proceeds to support development of its QTORIN rapamycin and QTORIN pitavastatin programs for rare skin diseases and vascular malformations.Benzinga · Mar 2, 2026

Palvella Therapeutics Announces Pricing of Upsized Public OfferingPalvella Therapeutics priced an upsized public offering of 1.6 million shares at $125 per share, raising $200 million in gross proceeds before underwriting costs. The clinical-stage biopharmaceutical company plans to use the funds to support development of its QTORIN rapamycin and QTORIN pitavastatin programs for rare skin diseases and vascular malformations. The offering is expected to close on February 27, 2026.GlobeNewswire Inc. · Feb 26, 2026

Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic MalformationsPalvella Therapeutics announced it will host a conference call on February 24, 2026, at 8:00am ET to discuss topline results from the Phase 3 SELVA clinical trial of QTORIN 3.9% rapamycin anhydrous gel for treating microcystic lymphatic malformations. The company plans to release results at 6:30am ET prior to the call.GlobeNewswire Inc. · Feb 23, 2026

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved TherapiesPalvella Therapeutics reported positive Phase 2 trial results for QTORIN™ rapamycin gel in treating cutaneous venous malformations, with 73% of participants showing improvement and no serious adverse events reported.GlobeNewswire Inc. · Dec 15, 2025

Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved TherapiesPalvella Therapeutics introduced a new product candidate, QTORIN™ pitavastatin, targeting disseminated superficial actinic porokeratosis (DSAP), a rare genetic skin disease with no current FDA-approved therapies. The company plans to initiate a Phase 2 clinical trial in the second half of 2026.GlobeNewswire Inc. · Nov 5, 2025

Ebenbuild Contributes Cutting-Edge Digital Lung Simulations to Pulmonary Fibrosis Drug DevelopmentEbenbuild's digital twin technology Twinhale was used in a study published in Nature Communications, demonstrating the potential of inhaled therapeutics for treating idiopathic pulmonary fibrosis (IPF). The simulations revealed how the novel inhaled Anticalin® protein PRS-220 can effectively target diseased lung tissue, paving the way for more efficient therapies for IPF patients.GlobeNewswire Inc. · Apr 9, 2025

PV

PVLAPalvella Therapeutics, Inc. Common Stock

PVLA

Pay with—

Available Balance0.00

Your PositionYou don't own any PVLA yet.

Related Tickers

Earnings